Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
B.A.D. Etf stock logo
BAD
B.A.D. Etf
$11.91
$11.91
$11.11
$13.72
$9.77M0.961,591 shsN/A
Amplify Treatments, Testing and Advancements ETF stock logo
GERM
Amplify Treatments, Testing and Advancements ETF
$19.16
$19.16
$15.67
$20.20
$9.58M0.841,891 shsN/A
SPAC and New Issue ETF stock logo
SPCX
SPAC and New Issue ETF
$24.86
+0.3%
$25.39
$22.40
$26.61
$9.45M0.051,329 shs2,914 shs
iShares Transition-Enabling Metals ETF stock logo
TMET
iShares Transition-Enabling Metals ETF
$24.23
+0.4%
$24.76
$20.90
$30.58
$9.72M0.13667 shs35 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
B.A.D. Etf stock logo
BAD
B.A.D. Etf
0.00%0.00%0.00%0.00%0.00%
Amplify Treatments, Testing and Advancements ETF stock logo
GERM
Amplify Treatments, Testing and Advancements ETF
0.00%0.00%0.00%0.00%+5.67%
SPAC and New Issue ETF stock logo
SPCX
SPAC and New Issue ETF
+0.34%+0.24%-0.98%+1.45%+5.18%
iShares Transition-Enabling Metals ETF stock logo
TMET
iShares Transition-Enabling Metals ETF
0.00%+1.98%-4.72%+6.53%-6.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
B.A.D. Etf stock logo
BAD
B.A.D. Etf
N/AN/AN/AN/AN/AN/AN/AN/A
Amplify Treatments, Testing and Advancements ETF stock logo
GERM
Amplify Treatments, Testing and Advancements ETF
N/AN/AN/AN/AN/AN/AN/AN/A
SPAC and New Issue ETF stock logo
SPCX
SPAC and New Issue ETF
N/AN/AN/AN/AN/AN/AN/AN/A
iShares Transition-Enabling Metals ETF stock logo
TMET
iShares Transition-Enabling Metals ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
B.A.D. Etf stock logo
BAD
B.A.D. Etf
0.00
N/AN/AN/A
Amplify Treatments, Testing and Advancements ETF stock logo
GERM
Amplify Treatments, Testing and Advancements ETF
0.00
N/AN/AN/A
SPAC and New Issue ETF stock logo
SPCX
SPAC and New Issue ETF
0.00
N/AN/AN/A
iShares Transition-Enabling Metals ETF stock logo
TMET
iShares Transition-Enabling Metals ETF
2.71
Moderate Buy$24.23N/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
B.A.D. Etf stock logo
BAD
B.A.D. Etf
N/AN/AN/AN/AN/AN/A
Amplify Treatments, Testing and Advancements ETF stock logo
GERM
Amplify Treatments, Testing and Advancements ETF
N/AN/AN/AN/AN/AN/A
SPAC and New Issue ETF stock logo
SPCX
SPAC and New Issue ETF
N/AN/AN/AN/AN/AN/A
iShares Transition-Enabling Metals ETF stock logo
TMET
iShares Transition-Enabling Metals ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
B.A.D. Etf stock logo
BAD
B.A.D. Etf
N/AN/A16.67N/AN/AN/AN/AN/A
Amplify Treatments, Testing and Advancements ETF stock logo
GERM
Amplify Treatments, Testing and Advancements ETF
N/AN/A7.10N/AN/AN/AN/AN/A
SPAC and New Issue ETF stock logo
SPCX
SPAC and New Issue ETF
N/AN/A142.96N/AN/AN/AN/AN/A
iShares Transition-Enabling Metals ETF stock logo
TMET
iShares Transition-Enabling Metals ETF
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
B.A.D. Etf stock logo
BAD
B.A.D. Etf
$0.080.67%N/AN/AN/A
Amplify Treatments, Testing and Advancements ETF stock logo
GERM
Amplify Treatments, Testing and Advancements ETF
$0.231.20%N/AN/AN/A
SPAC and New Issue ETF stock logo
SPCX
SPAC and New Issue ETF
$0.160.64%N/AN/AN/A
iShares Transition-Enabling Metals ETF stock logo
TMET
iShares Transition-Enabling Metals ETF
$6.3326.12%N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
B.A.D. Etf stock logo
BAD
B.A.D. Etf
N/A820,000N/ANot Optionable
Amplify Treatments, Testing and Advancements ETF stock logo
GERM
Amplify Treatments, Testing and Advancements ETF
N/A500,000N/ANot Optionable
SPAC and New Issue ETF stock logo
SPCX
SPAC and New Issue ETF
N/A380,000N/AOptionable
iShares Transition-Enabling Metals ETF stock logo
TMET
iShares Transition-Enabling Metals ETF
N/A400,000N/ANot Optionable

Recent News About These Companies

iShares Transition-Enabling Metals ETF
iShares Essential Metals Producers UCITS ETF
International ETFs To Reduce U.S. Market Exposure
How the (TMET) price action is used to our Advantage
(TMET) Proactive Strategies
iShares Transition-Enabling Metals ETF (TMET)
(TMET) Technical Pivots with Risk Controls
Trading (TMET) With Integrated Risk Controls
When (TMET) Moves Investors should Listen
(TMET) Investment Analysis and Advice
How to Take Advantage of moves in (TMET)

Media Sentiment Over Time

Top Headlines

View All Headlines
B.A.D. Etf stock logo

B.A.D. Etf NYSEARCA:BAD

$11.91 0.00 (0.00%)
As of 11/29/2023

The B.A.D. ETF (BAD) is an exchange-traded fund that is based on the EQM BAD index. The fund tracks a modified equal-weighted index of US-listed companies engaged in betting, alcohol, cannabis, and drugs. BAD was launched on Dec 22, 2021 and is managed by The BAD Investment Company.

Amplify Treatments, Testing and Advancements ETF stock logo

Amplify Treatments, Testing and Advancements ETF NYSEARCA:GERM

$19.16 0.00 (0.00%)
As of 08/6/2025

The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.

SPAC and New Issue ETF stock logo

SPAC and New Issue ETF NASDAQ:SPCX

$24.86 +0.09 (+0.34%)
Closing price 08/8/2025 03:56 PM Eastern
Extended Trading
$24.86 0.00 (0.00%)
As of 08/8/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The AXS SPAC and New Issue ETF (SPCX) is an exchange-traded fund that mostly invests in total market equity. The fund is an actively-managed fund that aims to provide a broad exposure to Special Purpose Acquisitions Corporations (SPACs) and newly-listed firms. SPCX was launched on Dec 16, 2020 and is managed by AXS Investments.

iShares Transition-Enabling Metals ETF stock logo

iShares Transition-Enabling Metals ETF NASDAQ:TMET

$24.23 +0.09 (+0.37%)
As of 08/7/2025 03:57 PM Eastern

The iShares Transition-Enabling Metals ETF (TMET) is an exchange-traded fund that is based on the ICE Clean Energy Transition Metals index. The fund tracks an index that measures the performance of a basket of exchange-traded metals futures contracts. The metals selected are those considered essential to clean energy technologies in supporting the transition to a low-carbon economy. TMET was launched on Sep 26, 2023 and is issued by BlackRock.